HIV/AIDS- Unwavering Committment
For more than 25 years, Merck has supported HIV/AIDS research, care access and partnerships around the world. Our commitment is unwavering. SOURCE: Merck
Medical
- Aerospace
- Agriculture
- Airlines
- Automotive
- Banking
- Broadcasting
- Business
- Chemicals
- Construction
- Education
- Electronics
- Energy
- Events
- Fashion
- Finance
- Food
- Golf
- Health
- Home
- Hospitality
- Hotels
- HR
- HVAC
- Insurance
- Jobs
- Logistics
- Manufacturing
- Marketing
- MBA
- Medical
- Oil
- Pharmaceuticals
- Press Releases
- Restaurants
- Retail
- Software
- Technology
- Trade Shows
- Travel
- Trucking
- Video
- Wireless
Elekta receives US FDA 510(k) clearance for its Monaco 5 treatment planning system
Monaco 5 radiation therapy treatment planning system unites capabilities in a single system STOCKHOLM, November 27, 2013 – Monaco® 5, the latest version of Elekta’s Monaco treatment planning system has received 510(k) clearance from the US Food & Drug Administration, making it available for purchase and use in the United States. “Monaco 5 consolidates the […]
Study Suggests Non-Invasive Stereotactic Ablative Body Radiotherapy May Be Suitable Alternative to Surgery for Early-Stage Lung Cancer Patients
Results of Review¹ by Harley Street and University College Hospital London Presented in Online Edition of ‘Radiotherapy and Oncology’ (Green Journal) LONDON, Nov. 27, 2013 /PRNewswire/ — Treating early stage non-small-cell lung cancer (NSCLC) patients with advanced radiotherapy appears to be a viable alternative to surgery, according to researchers who carried out a retrospective comparative study sponsored […]
FDA Approves Merck’s NOXAFIL® (posaconazole) Delayed-Release Tablets
WHITEHOUSE STATION, N.J. November 26, 2013 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice […]
Five Million Dollar Grant to Spaulding and Harvard Medical School Establishes The Ellen R. and Melvin J. Gordon Center for the Cure and Treatment of Paralysis
11/26/2013 – Boston, MA – When the public hears the term paralysis, it often conjures someone with a spinal cord injury. While an estimated 1.2 million Americans do suffer from paralysis due to a spinal cord injury, the number of Americans impacted by paralysis is even more widespread, with closer to 1 in 50 affected, according […]
Over 110 Attend First Varian Edge™ Radiosurgery Symposium to Discuss Advances in Stereotactic Radiosurgery and Stereotactic Ablative Radiotherapy
LISBON, Portugal, Nov. 26, 2013 /PRNewswire/ — Leading oncology centers have reported on advances in stereotactic radiosurgery (SRS) and stereotactic ablative radiotherapy (SABR) treatments at the first Varian Edge™ Radiosurgery Symposium, held at the Champalimaud Centre for the Unknown in Lisbon, Portugal. Experts from leading centers of excellence around the world presented details of the latest in advanced treatment […]
Widespread Acceptance and Use of Accuray’s Technologies Continue to Grow
More than 700 CyberKnife® and TomoTherapy® Systems Have Treated More Than Half a Million Patients Worldwide SUNNYVALE, Calif., November 25, 2013 – Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in global adoption of its CyberKnife® and TomoTherapy® Systems. Accuray has expanded its installed base to more than 700 systems worldwide which have been used to treat more than […]
Elekta opens state-of-the-art radiotherapy training center in Beijing
Learning and Innovation Center to address radiation therapy training needs STOCKHOLM, November 25 – Today, Chinese government officials, key Elekta radiotherapy customers in China and members of Elekta’s senior management inaugurated Elekta’s Learning and Innovation Center (LINC) in Beijing. The three-story, 1,800sq m (19,375sq ft) education and training facility is equipped with Elekta radiation therapy […]
Leading UK Cancer Center First in Europe to Introduce Latest Version of Varian’s TrueBeam™ Treatment System
TrueBeam 2.0 System Installed as The Clatterbridge Cancer Centre Treats 100th Lung Cancer Patient with Varian Radiosurgery Equipment Liverpool, UK, November 25th 2013 – Varian Medical Systems (NYSE: VAR) has installed the latest version of its advanced TrueBeam™ radiotherapy and radiosurgery system at The Clatterbridge Cancer Centre near Liverpool. The TrueBeam system 2.0 is the infrastructure that […]
Mylan-Biocon Receive First Indian Biosimilar Regulatory Approval for Herceptin®
PITTSBURGH, Nov. 25, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product. The product is a biosimilar to Roche’s Herceptin®, indicated for the treatment […]